Navigation Links
Vaginal atrophy drug Ospemifene found effective in breast cancer Prevention

Study results from two research papers have shown that use of the drug Ospemifene in combination with other anti-estrogens for vaginal atrophy reduces the incidence of breast cancer. // The study has been proved in mouse model and researchers are planning for a clinical trial.

DeGregorio and his colleagues at UC Davis compared the ability of ospemifene, tamoxifen and raloxifen to inhibit breast cancer in mice exposed to a carcinogen. Ospemifene and tamoxifen both inhibited breast cancer development. Results show that the mice in the ospemifene group were 95 percent less likely than mice in the control group to develop breast cancer and the study result is to be published in the Journal of Steroid Biochemistry and Molecular Biology.

The second study in which the first study author DeGregorio is also a co-author was led by Jeffrey P. Gregg, Associate professor of pathology and laboratory medicine at UC Davis, where they reported that Tamoxifen and Ospemifene both inhibited the growth and progression of pre-malignant breast lesions that closely resemble human ductal carcinomas in situ in mouse model.

Ospemifene is a Selective Estrogen Receptor Modulator (SERM), and is an effective anti-estrogen like tamoxifen and raloxifen which is used in the prevention and treatment of breast cancer which binds to estrogens. Ospemifene is now being developed by QuatRx Pharmaceuticals, an Ann Arbor, Mich.-based biopharmaceutical company that recently merged with Hormos Medical Corp. The drug is expected to enter Phase 3 clinical testing in the United States early next year for the treatment of vaginal atrophy, a common condition among postmenopausal women.

The advantage of Ospemifene over tamoxifen and raloxifen is due to its reduced side effects as raloxifen can cause hot flashes, insomnia and blood clots. Tamoxifen can cause endometrial cancer in patients undergoing tamoxifen therapy for breast cancer. But ospemifene have a unique estrogen-l ike effect on the vagina, yet a neutral effect on the endometrium, or lining of the uterus, and no aggravation or initiation of hot flashes.
'"/>




Related medicine news :

1. Vaginal Birth After C-section Dangerous For Both Mother And Baby
2. PET Scanner detects more Vaginal cancer than CT scans
3. Vaginal Vaccine may prevent periodic infections
4. Increased Risk Of HIV Transmission Following Vaginal Washing
5. Risk Of AIDS Rises With Vaginal Washes
6. Vaginal massage during pregnancy avoids Episiotomy procedure
7. Vaginal Gel That Protects Against HIV To Hit The Markets By 2010
8. Vaginal Delivery Should Be an Option after Multiple Cesareans
9. New Laparoscopic Surgery to Correct Vaginal Vault Prolapse Is Effectual Than the Conventional Surgery
10. Extra Vaginal Bleed After ‘C’ Section Can be Prevented By Contraceptive Pils
11. Risk of Hemorrhage Increased in Vaginally Born Babies
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/17/2017)... ... January 17, 2017 , ... In the crowded ... is a stand-out company for several differences from other mainstream brands. , ... demand, this is called 'Agile' manufacturing - http://www.leanproduction.com/agile-manufacturing.html . It allows them ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... events, Dr. Carol Francis re-releases powerfully uplifting interview with medical expert and prolific ... everyone endure and pass through tough times, Dr. Bernie Siegel energizes listeners to ...
(Date:1/17/2017)... ... ... SunView Software’s Service Smart Technology has been selected as a finalist for ... year, Pink Elephant recognizes a new product or service developed by an IT services ... opportunity. The award highlights original innovations that were released in 2016, either as a ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... enthusiasts at the National Association of Music Merchants (NAMM) winter trade show, Booth ... 2017. , Etymotic’s ER•4® has long been the gold standard for high-definition, in-ear ...
(Date:1/17/2017)... ... January 17, 2017 , ... Achieve TMS West, with multiple ... new office in San Clemente, California this month. Achieve TMS West is the ... treating individuals struggling with major depression. Depression impacts over 15 million adults in ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... 2017 Research and Markets has announced the ... report to their offering. ... The global artificial pancreas devices system market to ... Global Artificial Pancreas Devices System Market 2016-2020, has been prepared ... The report covers the market landscape and its growth prospects over ...
(Date:1/17/2017)... , Jan. 17, 2017 Paragon Bioservices received ... product development services for a variety of ... medical product development activities. The IDIQ mechanism ... pool for task order awards up to $159 ... in manufacturing and process development of biopharmaceuticals, is ...
(Date:1/17/2017)... 2017  Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... in a Phase 3 clinical trial comparing the efficacy ... in the prevention of hepatic veno-occlusive disease (VOD) in ... (HSCT) who are at high risk or at very ... will be conducted across approximately 100 medical centers in ...
Breaking Medicine Technology: